Intra-Cellular Therapies - Stock Price History | ITCI

Historical daily share price chart and data for Intra-Cellular Therapies since 2021 adjusted for splits. The latest closing stock price for Intra-Cellular Therapies as of October 22, 2021 is 43.13.
  • The all-time high Intra-Cellular Therapies stock closing price was 58.76 on November 27, 2015.
  • The Intra-Cellular Therapies 52-week high stock price is 44.80, which is 3.9% above the current share price.
  • The Intra-Cellular Therapies 52-week low stock price is 22.91, which is 46.9% below the current share price.
  • The average Intra-Cellular Therapies stock price for the last 52 weeks is 34.03.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intra-Cellular Therapies Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 22.7824 33.1200 33.1200 12.3100 31.8000 -7.32%
2019 11.7823 11.5200 38.4900 7.2600 34.3100 201.23%
2018 19.2115 15.1600 25.4900 10.3600 11.3900 -21.34%
2017 14.0433 15.7300 22.1000 9.2600 14.4800 -4.04%
2016 30.9926 53.6300 54.3200 10.8700 15.0900 -71.95%
2015 32.8543 17.5700 58.7600 16.4500 53.7900 204.76%
2014 16.2958 15.0000 20.2500 13.0800 17.6500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.508B $0.023B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76